Eli Lilly and Company $LLY Shares Bought by DAVENPORT & Co LLC

DAVENPORT & Co LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 11.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,891 shares of the company’s stock after buying an additional 3,753 shares during the quarter. DAVENPORT & Co LLC’s holdings in Eli Lilly and Company were worth $40,733,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pensionfund Sabic purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth about $1,827,000. David J Yvars Group lifted its stake in shares of Eli Lilly and Company by 1.4% in the 4th quarter. David J Yvars Group now owns 892 shares of the company’s stock valued at $959,000 after purchasing an additional 12 shares during the last quarter. Amplius Wealth Advisors LLC boosted its stake in Eli Lilly and Company by 3.4% during the fourth quarter. Amplius Wealth Advisors LLC now owns 1,027 shares of the company’s stock worth $1,104,000 after buying an additional 34 shares during the period. Abound Wealth Management boosted its position in shares of Eli Lilly and Company by 6.7% during the 4th quarter. Abound Wealth Management now owns 269 shares of the company’s stock worth $289,000 after purchasing an additional 17 shares during the period. Finally, RoundAngle Advisors LLC boosted its position in shares of Eli Lilly and Company by 4.7% during the fourth quarter. RoundAngle Advisors LLC now owns 2,177 shares of the company’s stock worth $2,340,000 after buying an additional 98 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $898.68 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company has a market capitalization of $849.09 billion, a PE ratio of 39.16, a P/E/G ratio of 1.06 and a beta of 0.40. The company has a 50-day simple moving average of $1,010.46 and a 200-day simple moving average of $960.96.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 earnings and revenue momentum — Coverage highlights Eli Lilly’s strong Q4 results and robust GLP‑1 sales that are driving top‑line and margin strength, supporting the company’s growth story. Firing on All Cylinders: Eli Lilly (NYSE:LLY) Q4 Earnings Lead the Way
• Positive Sentiment: Bullish long‑term thesis on GLP‑1 leadership — Retail/bullish analysis argues that Lilly’s leadership in obesity/GLP‑1 drugs makes it a durable growth compounder, reinforcing investor enthusiasm. Could Buying Eli Lilly Today Set You Up for Life?
• Positive Sentiment: Analyst model tweak — Erste Group slightly raised FY‑2026 EPS expectations for LLY (minor lift to forecasts), which supports consensus that Lilly’s earnings power is rising. MarketBeat: Eli Lilly analyst note
• Neutral Sentiment: Media/celebrity endorsement and market performance — Jim Cramer and other outlets are naming Lilly among top healthcare picks, and recent trading showed short‑term outperformance, which can attract flows but also create volatility. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Industry comparisons and valuation debate — Analyst pieces compare LLY with peers (Novo Nordisk, ABBV), highlighting strong growth but also elevated multiples — important context for investors weighing upside vs. valuation risk. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
• Neutral Sentiment: Investor letters and fund commentary reiterate GLP‑1 as the growth engine, but also note concentration risk (revenue tied to a few franchises). Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
• Negative Sentiment: Policy/reputation risk around GLP‑1s — Coverage raising the “societal obligation” and broader public debate about GLP‑1s can translate into regulatory scrutiny or reimbursement pressure, a potential near‑term headwind for sentiment. Eli Lilly and the ‘societal obligation’ of GLP-1s

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LLY. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 21st. Barclays started coverage on Eli Lilly and Company in a report on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 target price on the stock. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, CICC Research upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,221.44.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.